$7.09
0.85% yesterday
Nasdaq, Nov 07, 10:00 pm CET
ISIN
US09058V1035
Symbol
BCRX

BioCryst Pharmaceuticals, Inc. Stock price

$7.09
+0.14 2.01% 1M
-2.99 29.66% 6M
-0.43 5.72% YTD
-0.58 7.56% 1Y
-4.74 40.07% 3Y
+3.21 82.73% 5Y
-3.04 30.01% 10Y
-6.81 48.99% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
+0.06 0.85%
ISIN
US09058V1035
Symbol
BCRX
Industry

Key metrics

Basic
Market capitalization
$1.5b
Enterprise Value
$2.0b
Net debt
$470.0m
Cash
$260.0m
Shares outstanding
209.9m
Valuation (TTM | estimate)
P/E
negative | 79.8
P/S
2.7 | 2.3
EV/Sales
3.5 | 3.1
EV/FCF
2,785.9
P/B
negative
Financial Health
Equity Ratio
-97.1%
Return on Equity
18.7%
ROCE
19.4%
ROIC
36.5%
Debt/Equity
-1.7
Financials (TTM | estimate)
Revenue
$557.5m | $638.1m
EBITDA
$55.5m | $94.4m
EBIT
$54.2m | $103.9m
Net Income
$-35.7m | $18.5m
Free Cash Flow
$700.0k
Growth (TTM | estimate)
Revenue
45.9% | 41.6%
EBITDA
194.3% | 7,357.7%
EBIT
189.9% | 4,191.7%
Net Income
75.5% | 120.8%
Free Cash Flow
100.8%
Margin (TTM | estimate)
Gross
97.0%
EBITDA
10.0% | 14.8%
EBIT
9.7%
Net
-6.4% | 2.9%
Free Cash Flow
0.1%
More
EPS
$-0.2
FCF per Share
$0.0
Short interest
14.7%
Employees
580
Rev per Employee
$780.0k
Show more

Is BioCryst Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

BioCryst Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a BioCryst Pharmaceuticals, Inc. forecast:

15x Buy
88%
2x Hold
12%

Analyst Opinions

17 Analysts have issued a BioCryst Pharmaceuticals, Inc. forecast:

Buy
88%
Hold
12%

Financial data from BioCryst Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
558 558
46% 46%
100%
- Direct Costs 17 17
184% 184%
3%
541 541
44% 44%
97%
- Selling and Administrative Expenses 315 315
34% 34%
57%
- Research and Development Expense 171 171
15% 15%
31%
55 55
194% 194%
10%
- Depreciation and Amortization 1.28 1.28
13% 13%
0%
EBIT (Operating Income) EBIT 54 54
190% 190%
10%
Net Profit -36 -36
76% 76%
-6%

In millions USD.

Don't miss a Thing! We will send you all news about BioCryst Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioCryst Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
–   Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on pediatric patients and their caregivers – –  ORLADEYO oral granules demonstrated early and sustained reduction in HAE attacks over one year of treatment in second interim analysis of APeX-P – –  ORLADEYO oral granules are currently under review with U.S. FDA for ages 2 to
Neutral
GlobeNewsWire
3 days ago
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired employees restricted stock units (RSUs) covering an aggregate of 30,700 shares of BioCryst common stock. The RSUs were granted as of November 3, 2025, as inducements material to ea...
Neutral
GlobeNewsWire
3 days ago
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025, at 12:00 p.m.
More BioCryst Pharmaceuticals, Inc. News

Company Profile

BioCryst Pharmaceuticals, Inc. designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.

Head office United States
CEO Jon Stonehouse
Employees 580
Founded 1986
Website www.biocryst.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today